ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

No reading has been made of this study yet; what is shown is how the rules link it today.

9 links0 made here, not in the record9 judgments1 judge (the rules as one: Rule based)4 record changes seen
Rule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07605416Testing an ExperimentalApproach to Treat PatientsWith Plasma Cell Leukemia,The QUANTUM TrialNational Cancer Institute (NCIPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 29 · ClinicalTrials.gov record · Version of 2026-09-29Oct 7 · ClinicalTrials.gov record · Version of 2026-10-07Oct 26 · ClinicalTrials.gov record · Version of 2026-10-26Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Version of 2026-11-18CONDITIONSLeukemia, Plasma CellThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSCarfilzomibIntervention entry›As of now · Rule based · BackgroundBackgroundDaratumumab and Hyaluronida…Entry “Daratumumab and Recombinant Hu…›As of now · Rule based · BackgroundBackgroundDexamethasoneIntervention entry›As of now · Rule based · BackgroundBackgroundLenalidomideIntervention entry›As of now · Rule based · BackgroundBackgroundMelphalanIntervention entry›As of now · Rule based · BackgroundBackgroundPlerixaforIntervention entry›As of now · Rule based · BackgroundBackgroundRecombinant Granulocyte Col…Intervention entry›As of now · Rule based · BackgroundBackgroundTeclistamabIntervention entry›As of now · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Leukemia, Plasma Cell

From the registry record1 judgment on this link
Main condition (R9), from the registry to what was judged
RegistryLeukemia, Plasma Cell, as filedthe registry files the study under it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Sep 29The record itselfClinicalTrials.gov recordVersion of 2026-09-29Record change
Oct 7The record itselfClinicalTrials.gov recordVersion of 2026-10-07Record change
Oct 26The record itselfClinicalTrials.gov recordVersion of 2026-10-26Record change
Nov 18The record itselfClinicalTrials.gov recordVersion of 2026-11-18Record change
As of nowLeukemia, Plasma CellRule based · main-condition ruleMain conditionCurrent
As of nowCarfilzomibRule based · role ruleBackgroundCurrent
As of nowDaratumumab and Hyaluronidase-fihjRule based · role ruleBackgroundCurrent
As of nowDexamethasoneRule based · role ruleBackgroundCurrent
As of nowLenalidomideRule based · role ruleBackgroundCurrent
As of nowMelphalanRule based · role ruleBackgroundCurrent
As of nowPlerixaforRule based · role ruleBackgroundCurrent
As of nowRecombinant Granulocyte Colony-Stimulating FactorRule based · role ruleBackgroundCurrent
As of nowTeclistamabRule based · role ruleTestedCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.